Hidragon Pharma

Hidragon is a biotechnology company specializing in the discovery and development of next-generation targeted protein degradation (TPD) therapies, with a primary focus on molecular glues. The company utilizes its proprietary HIDRAGON platform, which enables high-throughput identification of degrader-induced protein-protein interactions to target previously undruggable proteins. By leveraging structural biology, cryo-electron microscopy, and computational chemistry, Hidragon aims to develop novel small molecule therapeutics for cancer and other life-threatening diseases. The company was founded by Dr. Ning Zheng, a leading expert in E3 ligase structural biology, and is headquartered in Suzhou, China. Hidragon's approach focuses on expanding the reach of TPD beyond traditional PROTACs by identifying glues that can modulate a wider array of disease-relevant targets. The firm has secured significant venture capital funding from top-tier investors to advance its diverse pipeline of preclinical programs toward the clinic.